Products - Blood conditions | Topic

Showing 13 products

Date | Sort by Title

Status: In developmentRemove ‘Status: In development’ filter

Patiromer for treating hyperkalaemia [ID877]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
5 February 2020
Avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure [ID1520]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
26 February 2020
Andexanet alfa for reversing anticoagulation [ID1101]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 June 2020
Zynteglo for treating transfusion-dependent beta-thalassaemia ID968
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
24 June 2020
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
11 November 2020
Management of gout
Status:
In development
Programme:
NICE guideline
Expected publication date:
4 April 2022
Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Volanesorsen for treating familial chylomicronaemia syndrome [ID1326]
Status:
In development
Programme:
Highly specialised technologies guidance
Expected publication date:
TBC
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis ID1186
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Caplacizumab for treating adults experiencing an episode of acquired thrombotic thrombocytopenic purpura [ID1185]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fedratinib for splenomegaly and symptoms in myelofibrosis [ID1501]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Blood conditions Products

Filter

Product type

Guidance programme

Status
1 selected

New and updated

Showing 13 products

Patiromer for treating hyperkalaemia [ID877]

Avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure [ID1520]

Andexanet alfa for reversing anticoagulation [ID1101]

Zynteglo for treating transfusion-dependent beta-thalassaemia ID968

Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596

Management of gout

Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]

Volanesorsen for treating familial chylomicronaemia syndrome [ID1326]

Mepolizumab for treating eosinophilic granulomatosis with polyangiitis ID1186

Caplacizumab for treating adults experiencing an episode of acquired thrombotic thrombocytopenic purpura [ID1185]

Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]

Fedratinib for splenomegaly and symptoms in myelofibrosis [ID1501]

L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]

Blood conditions Products

Filter

Product type

Guidance programme

Status1 selected

New and updated

Showing 13 products

Status
1 selected